To define the qualitative and quantitative toxicity and reversibility of toxicity of this combination and schedule. As a secondary objective to describe the nature of responses noted at any particular dose level. Excluding patients with less than 1 cm residual disease.
Patients can have either evaluable or measurable disease.
Patients should have gross residual disease that can be followed for response. The period between prior surgery, radiotherapy, or chemotherapy and the initiation of study drugs is required to be at least four weeks. Patients must have signed an informed consent. Patients with less than 1 cm residual disease. You will need Acrobat Reader available for viewing.